BMO Analyst Evan Seigerman on Pfizer's Obesity Drug Strategy and Market Competition

Pfizer's Entry into the Obesity Market

• 💡 Evan Seigerman of BMO Capital Markets is bullish on Pfizer's recent acquisition in the obesity drug space, viewing it as a long-awaited and credible move.
• 🎯 Pfizer's acquired portfolio includes once-monthly assets from the Metera portfolio, differentiating them from competitors like Eli Lilly and Novo Nordisk.
• 🔑 A notable advantage is Pfizer's oral peptide drug, which, unlike oral semaglutide, does not require fasting before administration.

Competition and Market Size

• 🚀 The obesity drug market is expected to be driven by volume, not price, with room for multiple competitors due to its immense size.
• ⚠️ While Novo Nordisk and Eli Lilly have more advanced programs, Pfizer's once-monthly and oral options could be competitive.
• 📈 Pricing pressure is already evident from both Eli Lilly and Novo Nordisk, highlighting the need for scale.

Obesity as a Gateway to Broader Health

• 🧠 Pharmaceutical companies are investing heavily in obesity treatments because it is a precursor to many other diseases.
• 🏥 Involvement in obesity drugs is seen as crucial for big pharma companies aiming to be successful and improve overall human health.
• 🛠️ Success in this market requires significant infrastructure, including a large field force and complex payer contracts.

Investor Sentiment on Novo Nordisk

• 📊 Investor sentiment towards Novo Nordisk has shifted significantly, becoming more bullish following recent data readouts.
• 💰 Investors are attracted to the valuation disconnect between Novo Nordisk and Eli Lilly, with Novo trading at a discount.
• 🔍 Interest is growing in the Evoke trial for oral semaglutide in Alzheimer's disease, with data expected in December.